GSK Branding and Brand Guidelines

The company’s more recent history has been defined by a deliberate narrowing of focus. On 18 July 2022, GSK completed the demerger of its Consumer Healthcare business, a joint venture roughly two-thirds owned by GSK and one-third by Pfizer that included household names like Sensodyne, Panadol and Aquafresh, into an independent public company called Haleon, in what was at the time the largest stock market listing in over a decade on the London Stock Exchange. The remaining company, simplified from GlaxoSmithKline to simply GSK plc, became fully focused on biopharmaceuticals and vaccines. By fiscal year 2025, GSK reported £32.67 billion in revenue and roughly 65,000 employees, and continues to describe its purpose as uniting ‘science, technology and talent to get ahead of disease together.’

GSK’s visual identity has changed twice since the 2000 merger, each time tracking a shift in the underlying business. The original 2000 logo paired an orange, tablet- or heart-shaped emblem with lowercase white lettering, still visibly tied to the recency of the corporate merger rather than standing as its own confident mark. In 2014, agency FutureBrand refined this into a softer, rounded heart-shaped orange emblem with ‘gsk’ set in lowercase Frutiger, a warmer, more optimistic mark that became one of the most recognised symbols in consumer and prescription healthcare over the following eight years.

The identity used today launched on 9 June 2022, timed deliberately to precede the Haleon demerger by about six weeks, designed by brand consultancy Wolff Olins around a new purpose statement, ‘Ahead Together’. Wolff Olins global executive creative director Emma Barratt described the brief as creating a system that would signal ‘extraordinary adaptability, of the human immune system, of tech, of GSK’s people’ while still carrying warmth. The redesign replaced the lowercase wordmark with uppercase ‘GSK’ letterforms, removed the capsule shape entirely so the letters stand alone, introduced a richer gradient orange, and added subtle curved connections between letterforms inspired directly by bioscience imagery and the adaptability of the human immune system. The logo now sits within a broader flexible system the company calls the ‘Signal’, built around forward-pointing shapes intended to visually echo the ‘ahead’ in the company’s new purpose line.

Alongside the logo, GSK commissioned a genuinely bespoke typeface, GSK Precision, developed with Wolff Olins and built by type foundry F37 (also credited as ‘Face37’ in some contemporary press) starting from F37’s existing typeface Jan. Its defining visual feature is a set of exaggerated ink traps, small cut-outs originally developed to stop ink bleeding into fine details at small print sizes, which GSK repurposed as a deliberate aesthetic signature, especially visible in the typeface’s distinctive ‘K’. The full family spans eight styles across Thin, Light, Regular and Bold weights (each with an italic), giving GSK a genuinely flexible system for everything from large hoardings to dense medical packaging.

Colour remains anchored by a single, distinctive orange (GSK calls it ‘Flamingo’, #F36633), a deliberate departure from the blues and greens common across pharmaceutical branding, chosen to signal energy and optimism, supported by a small set of neutrals (a warm off-white called Cararra, white, and a near-black ‘Cod Gray’) for text and contrast. Tone of voice, following the 2022 relaunch, aims to balance scientific credibility with approachability: clear, jargon-light language intended to read well for patients, healthcare professionals and investors alike, while still conveying the sense of progress and momentum behind the ‘get ahead of disease together’ purpose line.

GSK’s biopharma work gives the brand’s promise unusually concrete backing. Mosquirix, the world’s first vaccine against any parasitic disease, resulted from over 30 years of GSK research in partnership with PATH and funding support from the Bill & Melinda Gates Foundation, receiving a positive opinion from European regulators in 2015, WHO policy recommendation in 2021, and its first African rollout outside clinical trials, in Cameroon, in January 2024. GSK has committed to selling the vaccine at manufacturing cost plus a maximum 5% margin, reinvested into further neglected-disease research rather than treated as a profit centre, a genuinely unusual commercial commitment for a public pharmaceutical company.

GSK’s website mirrors the 2022 identity’s priorities directly: GSK Precision’s ink-trap detailing keeps type legible at small sizes across devices, colour contrast is deliberately managed for accessibility, and italics are used sparingly to preserve readability, all built to make dense scientific and medical information feel structured rather than overwhelming for a broad, non-specialist audience.

The clearest lesson in GSK’s brand history is that a rebrand timed to a corporate separation can do real strategic work beyond aesthetics. By launching its new identity roughly six weeks before formally demerging Haleon, GSK gave employees, investors and the public a clear visual signal of what kind of company would be left once the consumer business departed, using the Wolff Olins system to answer a strategic question (what is GSK now?) that the demerger paperwork alone couldn’t.